0001437749-23-013580.txt : 20230510 0001437749-23-013580.hdr.sgml : 20230510 20230510160559 ACCESSION NUMBER: 0001437749-23-013580 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 60 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230510 DATE AS OF CHANGE: 20230510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioCardia, Inc. CENTRAL INDEX KEY: 0000925741 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 232753988 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38999 FILM NUMBER: 23906309 BUSINESS ADDRESS: STREET 1: 125 SHOREWAY ROAD STREET 2: SUITE B CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 650-226-0123 MAIL ADDRESS: STREET 1: 125 SHOREWAY ROAD STREET 2: SUITE B CITY: SAN CARLOS STATE: CA ZIP: 94070 FORMER COMPANY: FORMER CONFORMED NAME: Tiger X Medical, Inc. DATE OF NAME CHANGE: 20110616 FORMER COMPANY: FORMER CONFORMED NAME: Cardo Medical, Inc. DATE OF NAME CHANGE: 20081027 FORMER COMPANY: FORMER CONFORMED NAME: CLICKNSETTLE COM INC DATE OF NAME CHANGE: 20000823 10-Q 1 bcda20230331_10q.htm FORM 10-Q bcda20230331_10q.htm
0000925741 false --12-31 2023 Q1 0 0 45 00009257412023-01-012023-03-31 thunderdome:item iso4217:USD 0000925741us-gaap:RelatedPartyMember2022-12-31 0000925741us-gaap:RelatedPartyMember2023-03-31 0000925741bcda:FundingAgreementMemberbcda:BSLFLLCMember2022-01-012022-03-31 0000925741bcda:FundingAgreementMemberbcda:BSLFLLCMember2023-01-012023-03-31 0000925741bcda:FundingAgreementMemberbcda:BSLFLLCMember2022-03-012022-03-29 00009257412022-01-012022-03-31 xbrli:shares 0000925741us-gaap:WarrantMember2022-01-012022-03-31 0000925741us-gaap:WarrantMember2023-01-012023-03-31 0000925741us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-31 0000925741us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-31 0000925741us-gaap:EmployeeStockOptionMember2022-01-012022-03-31 0000925741us-gaap:EmployeeStockOptionMember2023-01-012023-03-31 utr:Y 0000925741us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-31 0000925741us-gaap:RestrictedStockUnitsRSUMember2023-03-31 iso4217:USDxbrli:shares 00009257412023-03-31 0000925741us-gaap:RestrictedStockUnitsRSUMember2022-12-31 0000925741bcda:EmployeesNonemployeesAndNonemployeeDirectorsMember2023-01-012023-03-31 0000925741bcda:EmployeesNonemployeesAndNonemployeeDirectorsMember2023-03-31 00009257412022-12-31 00009257412022-01-012022-12-31 0000925741us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-03-31 0000925741us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-03-31 0000925741us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-31 0000925741us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-31 0000925741bcda:SalesAgreementWithCantorFitzgeraldCoCantorMember2022-01-012022-12-31 0000925741bcda:SalesAgreementWithCantorFitzgeraldCoCantorMember2023-03-312023-03-31 0000925741bcda:SalesAgreementWithCantorFitzgeraldCoCantorMember2022-04-122022-04-12 xbrli:pure 0000925741bcda:SalesAgreementWithCantorFitzgeraldCoCantorMember2022-04-12 0000925741bcda:PurchaseAgreementWithLincolnParkMember2021-03-292021-03-29 0000925741bcda:UnderwritersMember2021-03-292021-03-29 0000925741bcda:PurchaseAgreementWithLincolnParkMember2021-03-29 00009257412021-01-012022-03-31 00009257412022-01-012023-03-31 0000925741us-gaap:LeaseholdImprovementsMember2022-12-31 0000925741us-gaap:LeaseholdImprovementsMember2023-03-31 0000925741us-gaap:FurnitureAndFixturesMember2022-12-31 0000925741us-gaap:FurnitureAndFixturesMember2023-03-31 0000925741bcda:LaboratoryAndManufacturingEquipmentMember2022-12-31 0000925741bcda:LaboratoryAndManufacturingEquipmentMember2023-03-31 0000925741bcda:ComputerEquipmentAndSoftwareMember2022-12-31 0000925741bcda:ComputerEquipmentAndSoftwareMember2023-03-31 0000925741us-gaap:FairValueMeasurementsRecurringMember2022-12-31 0000925741us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-31 0000925741us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-31 0000925741us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-31 0000925741us-gaap:DemandDepositsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-31 0000925741us-gaap:DemandDepositsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-31 0000925741us-gaap:DemandDepositsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-31 0000925741us-gaap:DemandDepositsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-31 0000925741us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-31 0000925741us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-31 0000925741us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-31 0000925741us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-31 0000925741us-gaap:FairValueMeasurementsRecurringMember2023-03-31 0000925741us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-31 0000925741us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-31 0000925741us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-31 0000925741us-gaap:DemandDepositsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-31 0000925741us-gaap:DemandDepositsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-31 0000925741us-gaap:DemandDepositsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-31 0000925741us-gaap:DemandDepositsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-31 0000925741bcda:SavingsAccountMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-31 0000925741bcda:SavingsAccountMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-31 0000925741bcda:SavingsAccountMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-31 0000925741bcda:SavingsAccountMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-31 0000925741us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-31 0000925741us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-31 0000925741us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-31 0000925741us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-31 00009257412023-12-31 00009257412022-03-31 00009257412021-12-31 0000925741us-gaap:RetainedEarningsMember2023-03-31 0000925741us-gaap:AdditionalPaidInCapitalMember2023-03-31 0000925741us-gaap:CommonStockMember2023-03-31 0000925741us-gaap:RetainedEarningsMember2023-01-012023-03-31 0000925741us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-31 0000925741us-gaap:CommonStockMember2023-01-012023-03-31 0000925741us-gaap:RestrictedStockUnitsRSUMemberus-gaap:CommonStockMember2023-01-012023-03-31 0000925741bcda:ATMMember2023-01-012023-03-31 0000925741us-gaap:RetainedEarningsMemberbcda:ATMMember2023-01-012023-03-31 0000925741us-gaap:AdditionalPaidInCapitalMemberbcda:ATMMember2023-01-012023-03-31 0000925741us-gaap:CommonStockMemberbcda:ATMMember2023-01-012023-03-31 0000925741us-gaap:RetainedEarningsMember2022-12-31 0000925741us-gaap:AdditionalPaidInCapitalMember2022-12-31 0000925741us-gaap:CommonStockMember2022-12-31 0000925741us-gaap:RetainedEarningsMember2022-03-31 0000925741us-gaap:AdditionalPaidInCapitalMember2022-03-31 0000925741us-gaap:CommonStockMember2022-03-31 0000925741us-gaap:RetainedEarningsMember2022-01-012022-03-31 0000925741us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-31 0000925741us-gaap:RetainedEarningsMember2021-12-31 0000925741us-gaap:AdditionalPaidInCapitalMember2021-12-31 0000925741us-gaap:CommonStockMember2021-12-31 0000925741bcda:CollaborationAgreementMember2022-01-012022-03-31 0000925741bcda:CollaborationAgreementMember2023-01-012023-03-31 0000925741us-gaap:ProductMember2022-01-012022-03-31 0000925741us-gaap:ProductMember2023-01-012023-03-31 00009257412023-04-30 0000925741us-gaap:WarrantMember2023-01-012023-03-31 0000925741us-gaap:CommonStockMember2023-01-012023-03-31
 

 

 

  


 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

 

 


 

FORM 10-Q

 


 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2023

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number: 0-21419

 

 


 

BioCardia, Inc.

(Exact name of registrant as specified in its charter)

 


 

Delaware

23-2753988

(State or another jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification Number)

 

320 Soquel Way 

Sunnyvale, California 94085

(Address of principal executive offices including zip code)

 

(650) 226-0120

(Registrants telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 


 

1

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes ☒    No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes ☒    No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

       

Non-accelerated filer

Smaller reporting company

       
   

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes     No ☒

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which

registered

Common Stock, par value $0.001

Warrant to Purchase Common Stock

BCDA

BCDAW

The Nasdaq Capital Market

The Nasdaq Capital Market

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

There were 20,219,087 shares of the registrant’s Common Stock issued and outstanding as of April 30, 2023.

 

2

 

 

 

Part I.  

FINANCIAL INFORMATION

4
     

Item 1.

Unaudited Condensed Consolidated Financial Statements

4
 

Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022

4
 

Condensed Consolidated Statements of Operations for the three months ended March 31, 2023 and 2022

5
 

Condensed Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2023 and 2022

6
 

Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022

7
 

Notes to Unaudited Condensed Consolidated Financial Statements

8

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

14

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

21

Item 4.

Controls and Procedures

21
     

Part II. 

OTHER INFORMATION

22
   

Item 1.

Legal Proceedings

22

Item 1A.

Risk Factors

22

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

22

Item 3.

Defaults Upon Senior Securities

22

Item 4.

Mine Safety Disclosures

22

Item 5.

Other Information

22

Item 6.

Exhibits

22
     

EXHIBIT INDEX

22

SIGNATURES

23

 

 

FORWARD-LOOKING INFORMATION

 

This Quarterly Report on Form 10-Q, or report, contains forward-looking statements within the meaning of the U.S. federal securities laws that involve risks and uncertainties. Certain statements contained in this report are not purely historical including, without limitation, statements regarding our expectations, beliefs, intentions, anticipations, commitments or strategies regarding the future that are forward-looking. These statements include those discussed in Item 2, Managements Discussion and Analysis of Financial Condition and Results of Operations, including Critical Accounting Policies and Estimates, Results of Operations, Liquidity and Capital Resources, and Future Funding Requirements, and elsewhere in this report.

 

In this report, the words may, could, would, might, will, should, plan, forecast, anticipate, believe, expect, intend, estimate, predict, potential, continue, future, moving toward or the negative of these terms or other similar expressions also identify forward-looking statements. Our actual results could differ materially from those forward-looking statements contained in this report as a result of a number of risk factors including, but not limited to, those listed in our Annual Report on Form 10-K for the year ended December 31, 2022, which is incorporated by reference herein, and elsewhere in this report. You should carefully consider these risks, in addition to the other information in this report and in our other filings with the SEC. All forward-looking statements and reasons why results may differ included in this report are made as of the date of this report, and we undertake no obligation to update any such forward-looking statement or reason why such results might differ after the date of this Quarterly Report on Form 10-Q, except as required by law.

 

3

 

 

PART I. FINANCIAL INFORMATION

 

ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

 

BIOCARDIA, INC.

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

 

   

March 31,

   

December 31,

 

 

 

2023

   

2022

 
   

(unaudited)

         
Assets                
Current assets:                

Cash and cash equivalents

  $ 4,857     $ 7,363  

Accounts receivable, net of allowance for doubtful accounts of $11 as of both March 31, 2023 and December 31, 2022

    153       201  

Prepaid expenses and other current assets

    279       300  

Total current assets

    5,289       7,864  

Property and equipment, net

    158       170  

Operating lease right-of-use asset, net

    1,509       1,588  

Other assets

    172       171  

Total assets

  $ 7,128     $ 9,793  
Liabilities and Stockholders Equity                
Current liabilities:                

Accounts payable

  $ 861     $ 683  

Accrued expenses and other current liabilities

    2,472       2,246  

Deferred revenue

    340       341  

Operating lease liability - current

    327       315  

Total current liabilities

    4,000       3,585  

Operating lease liability - noncurrent

    1,228       1,316  

Total liabilities

    5,228       4,901  
Commitments and contingencies (Notes 1, 2, 5 and 12)            
Stockholders’ equity:                

Preferred stock, $0.001 par value, 25,000,000 shares authorized and no shares issued and outstanding as of March 31, 2023 and December 31, 2022

           

Common stock, $0.001 par value, 100,000,000 shares authorized, 20,202,005 and 20,076,773 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively

    20       20  

Additional paid-in capital

    145,985       145,476  

Accumulated deficit

    (144,105 )     (140,604 )
Total stockholders’ equity     1,900       4,892  
Total liabilities and stockholders’ equity   $ 7,128     $ 9,793  

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

4

 

 

BIOCARDIA, INC.

Condensed Consolidated Statements of Operations

(In thousands, except share and per share amounts)

(unaudited)

 

   

Three months ended

 
   

March 31,

 
   

2023

   

2022

 
Revenue:                

Net product revenue

  $     $ 1  

Collaboration agreement revenue

    64       59  

Total revenue

    64       60  
Costs and expenses:                

Research and development

    2,384       2,186  

Selling, general and administrative

    1,190       1,201  

Total costs and expenses

    3,574       3,387  

Operating loss

    (3,510 )     (3,327 )
Other income (expense):                

Total other income, net

    9       2  

Net loss

  $ (3,501 )   $ (3,325 )
                 

Net loss per share, basic and diluted

  $ (0.17 )   $ (0.19 )
                 

Weighted-average shares used in computing net loss per share, basic and diluted

    20,177,167       17,066,068  

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

5

 

 

BIOCARDIA, INC.

Condensed Consolidated Statements of Stockholders’ Equity 

(In thousands, except share amounts)

(unaudited)

 

   

Common stock

   

Additional

   

Accumulated

         
   

Shares

   

Cost

   

paid-in capital

   

deficit

   

Total

 

Balance at December 31, 2021

    16,871,265     $ 17     $ 139,055     $ (128,697 )   $ 10,375  

Share-based compensation

                319             319  

Net loss

                      (3,325 )     (3,325 )

Balance at March 31, 2022

    16,871,265     $ 17     $ 139,374     $ (132,022 )   $ 7,369  
                                         

Balance at December 31, 2022

    20,076,773     $ 20     $ 145,476     $ (140,604 )   $ 4,892  

Sale of common stock under ATM, net of issuance costs of $13

    106,241             231             231  

Exercise of common stock options

    199                          

Restricted stock units vested and issued

    18,792                          

Share-based compensation

                278             278  

Net loss

                      (3,501 )     (3,501 )

Balance at March 31, 2023

    20,202,005     $ 20     $ 145,985     $ (144,105 )   $ 1,900  

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

6

 

 

 

BIOCARDIA, INC.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(unaudited)

 

   

Three months ended March 31,

 
   

2023

   

2022

 
Operating activities:                

Net loss

  $ (3,501 )   $ (3,325 )
Adjustments to reconcile net loss to net cash used in operating activities:                

Depreciation

    22       16  

Reduction in the carrying amount of right-of-use assets

    79       71  

Share-based compensation

    278       319  
Changes in operating assets and liabilities:                

Accounts receivable

    48       (179 )

Prepaid expenses and other current assets

    20       57  

Other receivable due from related party

           

Accounts payable

    345       257  

Accrued expenses and other current liabilities

    226       (201 )

Deferred revenue

    (1 )     101  

Operating lease liability

    (76 )     (29 )

Net cash used in operating activities

    (2,560 )     (2,913 )
Investing activities:                

Purchase of property and equipment

    (10 )     (29 )

Net cash used in investing activities

    (10 )     (29 )
Financing activities:                

Proceeds from sales of common stock

    244        

Issuance costs of sale of common stock

    (180 )      

Net cash provided by financing activities

    64        

Net change in cash and cash equivalents

    (2,506 )     (2,942 )

Cash and cash equivalents at beginning of period

    7,363       12,872  

Cash and cash equivalents at end of period

  $ 4,857     $ 9,930  
Supplemental disclosure of noncash investing and financing activities:                

Unpaid issuance costs of common stock

  $ 6     $  

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

7

 

 

BioCardia, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

 

 

(1)

Summary of Business and Basis of Presentation

 

 

(a)

Description of Business

   

 

   

BioCardia, Inc. (we, us, our, BioCardia or the Company), is a clinical-stage company focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. We are advancing two cell therapy platforms derived from bone marrow in clinical trials today. Our CardiAMP® autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Our neurokinin-1 receptor positive (NK1R+) allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as an “off the shelf” cell therapy for two clinical indications: the treatment of ischemic HFrEF and for acute respiratory distress syndrome (ARDS). Our autologous CardiAMP and our allogeneic NK1R+ cell therapies intended for cardiac indications of HFrEF and CMI are enabled by our Helix™ minimally invasive intramyocardial therapeutic delivery platform. We partner this therapeutic delivery platform selectively with others seeking to develop biotherapeutic interventions for local delivery to the heart. To date, we have devoted substantially all our resources to research and development efforts relating to our therapeutic candidates and biotherapeutic delivery systems including conducting clinical trials, developing manufacturing and sales capabilities, in-licensing related intellectual property, providing general and administrative support for these operations and protecting our intellectual property.

   

 

   

We manage our operations as a single segment for the purposes of assessing performance and making operating decisions.

 

 

 

(2)

Significant Accounting Policies

 

 

(a)

Basis of Preparation

   

 

   

The accompanying condensed consolidated balance sheets, statements of operations, stockholders’ equity, and cash flows as of March 31, 2023, and for the three months ended March 31, 2023 and 2022 are unaudited. The condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial information and on a basis consistent with the annual financial statements and, in the opinion of management, reflect all adjustments which include only normal recurring adjustments, necessary to present fairly its financial position as of March 31, 2023, results of operations for the three months ended March 31, 2023 and 2022, and cash flows for the three months ended March 31, 2023 and 2022. The results for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the year ended December 31, 2023 or for any other interim period or for any other future year.

 

These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 29, 2023. 

 

 

(b)

Liquidity  Going Concern

   

 

   

We have incurred net losses and negative cash flows from operations since our inception and had an accumulated deficit of approximately $144.1 million as of March 31, 2023. Management expects operating losses and negative cash flows to continue through at least the next several years. We expect to incur increasing costs as we advance our trials and development activities. Therefore, absent additional funding, management believes cash and cash equivalents of $4.9 million as of March 31, 2023 are not sufficient to fund the Company’s planned expenditures and meet its obligations beyond the third quarter of 2023. These factors raise substantial doubt about our ability to continue as a going concern beyond one year from the date these financial statements are issued. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Our ability to continue as a going concern and to continue further development of our therapeutic candidates beyond the third quarter of 2023 will require us to raise additional capital. We plan to raise additional capital, potentially including debt and equity arrangements, to finance our future operations. While management believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt, these plans are not entirely within its control and cannot be assessed as being probable of occurring. If adequate funds are not available, we may be required to reduce operating expenses, delay or reduce the scope of our product development programs, obtain funds through arrangements with others that may require us to relinquish rights to certain of our technologies or products that we would otherwise seek to develop or commercialize, or cease operations.

 

8

 

 

(c)

Use of Estimates

   

 

   

The preparation of the financial statements in accordance with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include share-based compensation, the useful lives of property and equipment, right-of-use assets and related liabilities, incremental borrowing rate, allowances for doubtful accounts and sales returns, clinical accruals and assumptions used for revenue recognition.

 

 

(d)

Principles of Consolidation

   

 

   

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, BioCardia Lifesciences, Inc. All intercompany accounts and transactions have been eliminated during the consolidation process.

 

 

(e)

Concentration of Credit Risk

   

Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Our cash at times exceeds federally insured limits of $250,000 per customer. On March 31, 2023, substantially all of our cash was held by one financial institution and the amount on deposit was approximately $4.5 million in excess of FDIC insurance limits. We have not recognized any losses from credit risks on such accounts since inception.

 

Silicon Valley Bank (SVB) was closed on March 10, 2023 by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (FDIC) as receiver. As of March 31, 2023, the Company has transferred substantially all of its cash and cash equivalents from SVB to another financial institution and does not believe it will be impacted by the closure of SVB.

 

 

(f)

Changes to Significant Accounting Policies

   

 

   

Our significant accounting policies are described in Note 2 of the notes to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022 filed March 29, 2023. There have been no changes to those policies.

 

 

(g)

Recent Accounting Pronouncements

   

 

   

Recent accounting pronouncements issued by the Financial Accounting Standards Board (FASB), including its Emerging Issues Task Force, did not or are not believed by management to have a material impact on our financial statement presentation or disclosures.

 

 

 

(3)

Fair Value Measurement

 

   

The fair value of financial instruments reflects the amounts that we estimate to receive in connection with the sale of an asset or paid in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). We follow a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into the following three levels:

 

   

Level 1 – quoted prices in active markets for identical assets and liabilities.

 

   

Level 2 – observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

   

Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

9

 

   

The following table sets forth the fair value of our financial assets measured on a recurring basis and indicates the fair value hierarchy utilized to determine such fair value (in thousands):

 

   

As of March 31, 2023

 
                                 
   

Level 1

   

Level 2

   

Level 3

   

Total

 
Assets:                                

Money market funds

  $ 20     $     $     $ 20  

Cash in savings account

                      4,508  

Cash in checking account

                      329  

Total cash and cash equivalents

  $ 20     $     $     $ 4,857  
                                 

 

   

As of December 31, 2022

 
   

Level 1

   

Level 2

   

Level 3

   

Total

 
Assets:                                

Money market funds

  $ 6,893     $     $     $ 6,893  

Cash in checking account

                      470  

Total cash and cash equivalents

  $ 6,893     $     $     $ 7,363  

 

 

 

(4)

Property and Equipment, Net

 

   

Property and equipment, net consisted of the following (in thousands):

 

   

March 31,

   

December 31,

 
   

2023

   

2022

 

Computer equipment and software

  $ 171     $ 161  

Laboratory and manufacturing equipment

    575       575  

Furniture and fixtures

    27       27  

Leasehold improvements

    26       26  

Property and equipment, gross

    799       789  

Less accumulated depreciation

    (641 )     (619 )

Property and equipment, net

  $ 158     $ 170  

 

   

Depreciation expense totaled $22,000 and $16,000 for the three months ended March 31, 2023 and 2022, respectively.

  

 

 

(5)

Operating Lease Right-of-Use Asset, Net

 

   

In December 2021, we entered into a lease related to a property lease for our laboratory and corporate offices, which expires in January 2027, with an option for us to extend a further 36 months after expiration. Our lease agreements do not contain any material residual guarantees or material restrictive covenants. We determine if an arrangement is a lease at inception by assessing whether it conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

 

   

Right-of-use (ROU) assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The Company’s lease does not provide an implicit rate. We used an adjusted historical incremental borrowing rate, based on the information available at the approximate lease commencement date, to determine the present value of lease payments. Variable rent expense is made up of expenses for common area maintenance and shared utilities and were not included in the determination of the present value of lease payments. We have no finance leases.

 

   

Our lease expense was $121,000 for the each of three months ended March 31, 2023 and 2022. The cash paid under the operating lease for base rent for the three months ended March 31, 2023 and 2022 was $118,000 and $97,000, respectively. On March 31, 2023, the weighted average remaining lease term was 3.84 years, and the weighted average discount rate was 10.74%.

 

10

 

   

Future minimum lease payments under the operating lease as of March 31, 2023 were as follows (in thousands):

 

Remainder of 2023

  $ 114  

2024

    485  

2025

    499  

2026

    514  

2027

    44  

Total undiscounted lease payments

  $ 1,656  

Less imputed interest

    101  

Total operating lease liabilities

  $ 1,555  

 

 

 

(6)

Accrued Expenses and Other Current Liabilities

 

Accrued expenses and other current liabilities consisted of the following (in thousands):

 

   

March 31,

   

December 31,

 
   

2023

   

2022

 

Accrued expenses

  $ 38     $ 157  

Accrued salaries and employee benefits

    1,100       899  

Accrued clinical trial costs

    693       548  

Grant liability

    518       534  

Customer deposits

    90       90  

Payable to related party

    33       18  

Total

  $ 2,472     $ 2,246  

 

 

 

(7)

Stockholders Equity

 

Warrants - Set forth below is a table of activity of warrants for common stock and the related weighted average exercise price per warrant.

 

   

Number of

   

Weighted

 
   

Common Stock

   

Average

 
   

Warrants

   

Exercise Price

 

Balance as of December 31, 2022

    2,424,724     $ 6.36  

Warrants for common stock sold

           

Warrants for common stock exercised

           

Balance as of March 31, 2023

    2,424,724     $ 6.36  

 

Lincoln Park Capital stock purchase agreement - On March 29, 2021, we entered into a purchase agreement with Lincoln Park Capital Fund, LLC (Lincoln Park) (Purchase Agreement) and a registration rights agreement (Registration Rights Agreement), pursuant to which we have the right to sell to Lincoln Park shares of our common stock having an aggregate value of up to $20 million, subject to certain limitations and conditions in the Purchase Agreement.

 

Pursuant to the Purchase Agreement in March 2021, Lincoln Park purchased 373,832 shares of common stock, at a price of $5.35 per share, for a total gross purchase price of $2 million (Initial Purchase) and we issued 80,000 shares of common stock as commitment shares, which included 5,000 commitment shares issued on a pro rata basis for the initial $2 million purchase.

 

As of March 31, 2023, we had not sold any common stock to Lincoln Park under the Purchase Agreement other than the Initial Purchase.

 

11

 

Cantor Fitzgerald Sales agreement - On April 12, 2022, we entered into a sales agreement (Sales Agreement) with Cantor Fitzgerald & Co. (Cantor) as the sales agent, pursuant to which we may offer and sell, from time to time, through Cantor, shares of common stock having an aggregate offering price of up to $10.5 million (ATM Offering). We are not obligated to sell any common stock shares pursuant to the Sales Agreement. Under the terms of the Sales Agreement, we pay Cantor a commission of 3% of the aggregate proceeds from the sale of shares and reimburse certain legal fees. We filed a prospectus supplement under our existing registration statement covering the offer and sale of up to $10.5 million of common stock, of which approximately $8.5 million was still available for offer and sale as of March 31, 2023.

 

During the three months ended March 31, 2023, we sold 106,241 shares of common stock under the ATM Offering at then-market prices for total gross proceeds of $244,000, with net issuance costs of $13,000.

 

 

 

(8)

Share-Based Compensation

 

The share-based compensation expense is recorded in research and development, and selling, general and administrative expenses based on the employee's or non-employee’s respective function. No share-based compensation was capitalized during the periods presented. Share-based compensation expense for the three months ended March 31, 2023 and 2022 was recorded as follows (in thousands):

 

   

Three months ended

 
   

March 31,

 
   

2023

   

2022

 

Research and development

  $ 139     $ 127  

Selling, general and administrative

    139       192  

Total share-based compensation

  $ 278     $ 319  

 

The following table summarizes the activity of stock options and related information:

 

   

Options outstanding

                 
   

Number of

shares

   

Weighted

average

exercise

price

   

Weighted

average

remaining

contractual

term (years)

   

Aggregate

intrinsic value
(in thousands)

 
                                 

Balance, December 31, 2022

    2,182,708     $ 4.04       7.5     $ 343  

Stock options exercised

    (199 )     1.49                  

Stock options forfeited

    (14,059 )     2.77                  

Balance, March 31, 2023

    2,168,450     $ 4.05       7.3     $ 256  

Exercisable, March 31, 2023

    1,241,371     $ 5.27       6.3     $ 49  

 

Unrecognized share-based compensation for employee and nonemployee options granted through March 31, 2023 is approximately $1.8 million to be recognized over a remaining weighted average service period of 2.2 years.

 

Share-Based Compensation (RSUs)

 

The following summarizes the activity of non-vested RSUs:

 

           

Weighted

 
           

average

 
           

grant date

 
   

Number of

   

fair value

 
   

shares

   

per share

 

Balance, December 31, 2022

    21,526     $ 4.33  

RSUs released

    (18,792 )     4.34  

Balance, March 31, 2023

    2,734     $ 4.26  

 

RSUs vested and settled are converted into the Company’s common stock on a one-for-one basis. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The related compensation expense, which is based on the grant date fair value of our common stock multiplied by the number of units granted, is recognized ratably over the period during which the vesting restrictions lapse. Unrecognized share-based compensation for employee and nonemployee RSUs granted through March 31, 2023 is approximately $1,000 to be recognized over a remaining weighted average service period of 0.1 years.

 

12

 

 

(9)

Net Loss per Share

 

Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding and fully vested restricted stock units. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Common stock equivalents are comprised of unvested restricted stock units, warrants to purchase common stock and options outstanding under the stock option plans. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding since the effects of potentially dilutive securities are antidilutive due to the net loss position.

 

The following outstanding common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:

 

   

March 31,

 
   

2023

   

2022

 
                 

Stock options to purchase common stock

    2,168,450       1,616,364  

Unvested restricted stock units

    2,734       5,468  

Common stock warrants

    2,424,724       2,424,724  

Total

    4,595,908       4,046,556  

 

 

 

(10)

Income Taxes

 

During the three months ended March 31, 2023 and 2022, there was no income tax expense or benefit for federal or state income taxes in the accompanying condensed consolidated statements of operations due to our net loss and a full valuation allowance on the resulting deferred tax assets.

 

As of March 31, 2023, we retain a full valuation allowance on our deferred tax assets in all jurisdictions. The realization of our deferred tax assets depends primarily on our ability to generate future taxable income which is uncertain. We do not believe that our deferred tax assets are realizable on a more-likely-than-not basis; therefore, the net deferred tax assets have been fully offset by a valuation allowance.

 

 

 

(11)

Related Party Transactions

 

On April 9, 2020, we entered into a Litigation Funding Agreement (Funding Agreement) with BSLF, L.L.C. (Funder), an entity owned and controlled by Andrew Blank, Chair of BioCardia’s board of directors, for the purpose of funding our legal proceedings and any and all claims, actions and/or proceedings relating to or arising from the case captioned Boston Scientific Corp., et al., v. BioCardia Inc., Case No. 3:19-05645-VC, U.S.D.C., N. D. Cal (the Litigation). On April 12, 2021, all parties to the Litigation entered into a confidential settlement agreement and all claims were dismissed.

 

In March 2022, we entered into settlement agreements with our litigation service providers and the Funder to terminate the Funding Agreement and conclude on all remaining matters thereunder (the Litigation Funding Settlement). Under the terms of the confidential agreements, litigation and corporate counsel provided credits and refunds of legal fees, which offset the amounts owed to us by the Funder under the Funding Agreement, and provided up to $300,000 in future discounts on legal services which are remitted to the Funder on a quarterly basis. During the three months ended March 31, 2023, and 2022, we received discounts totaling $33,000 and zero, respectively, with $33,000 and $18,000 recorded as a related party payable in accrued expenses and other current liabilities as of March 31, 2023 and December 31, 2022, respectively.

 

 

 

(12)

Contingencies and Uncertainties

 

Contingencies - We may be subject to various claims, complaints, and legal actions that arise from time to time in the normal course of business. Management is not aware of any current legal or administrative proceedings that are likely to have an adverse effect on our business, financial position, results of operations, or cash flows.

 

Uncertainties - The results for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any other interim period or for any other future year, particularly in light of COVID-19 and its impact on domestic and global economies. Governmental and business reactions to the pandemic, and resulting economic disruptions, have the potential to materially impact our business and influence our business decisions. While the impact of COVID-19 did not have a material adverse effect on our financial position or results of operations for the periods presented, our future assessment of the magnitude and duration of COVID-19 and related factors, could result in material impacts to our financial statements in future reporting periods.

 

13

 

 

 

ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS                                                   

 

The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q. This discussion contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any and all statements contained in this Quarterly Report that are not statements of historical fact may be deemed forward-looking statements. Terms such as may, might, would, should, could, project, estimate, pro-forma, predict, potential, strategy, anticipate, attempt, develop, plan, help, believe, continue, intend, expect, future and terms of similar import (including the negative of any of the foregoing) may be intended to identify forward-looking statements. However, not all forward-looking statements may contain one or more of these identifying terms. Forward-looking statements in this Quarterly Report may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the development of our cell therapy systems and our clinical trials, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) our ability to raise additional capital, (iv) our future financial performance, including any such statement contained in a discussion and analysis of financial condition by management or in the results of operations included pursuant to the rules and regulations of the SEC and (vi) the assumptions underlying or relating to any statement described in points (i) (iv) above. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and elsewhere in this Quarterly Report on Form 10-Q, those listed in our Annual Report on Form 10-K for the year ended December 31, 2022, which is incorporated by reference herein. Historical results are not necessarily indicative of future results. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Quarterly Report on Form 10-Q to conform these statements to actual results or to changes in our expectations.    

 

Overview

 

We are a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. We are advancing two cell therapy platforms derived from bone marrow in clinical trials today. Our CardiAMP® autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Our neurokinin-1 receptor positive (NK1R+) allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as an “off the shelf” cell therapy for two clinical indications: the treatment of ischemic HFrEF and for acute respiratory distress syndrome (ARDS).

 

Our autologous CardiAMP and our allogeneic NK1R+ cell therapies intended for cardiac indications of HFrEF and CMI are enabled by our Helix™ minimally invasive intramyocardial therapeutic delivery platform. We selectively partner this therapeutic delivery platform with others seeking to develop biotherapeutic interventions for local delivery to the heart.

 

To date, we have devoted substantially all of our resources to research and development efforts relating to our therapeutic candidates and biotherapeutic delivery systems, including conducting clinical trials, developing manufacturing and sales capabilities, in-licensing related intellectual property, providing general and administrative support for these operations and protecting our intellectual property. We have also generated modest revenues from sales of our approved products. We have funded our operations primarily through the sales of equity and convertible debt securities, and certain government and private grants.

 

CardiAMP Autologous Cell Therapy for Ischemic Heart Failure and for Chronic Myocardial Ischemia (BCDA-02)

 

The CardiAMP Cell Therapy Heart Failure Trial is a Phase III, multi-center, randomized, double-blinded, sham-controlled study of up to 260 patients at up to 40 centers in the United States and Canada, which includes a 10-patient roll-in cohort. The Phase III pivotal trial, which was granted Breakthrough designation by the U.S. Food and Drug Administration (FDA), is designed to provide the primary support for the safety and efficacy of the CardiAMP Cell Therapy System for the treatment of heart failure with HFrEF (BCDA-01). The primary endpoint is an outcomes composite score based on a three-tiered Finkelstein-Schoenfeld hierarchical analysis. The tiers, starting with the most serious events, would be (1) all-cause death, including cardiac death equivalents such as heart transplant or left ventricular assist device placement, ordered by time to event; (2) non-fatal Major Adverse Coronary and Cerebrovascular Events (MACCE), excluding those deemed procedure-related occurring within the first seven days post-procedure (heart failure hospitalization, stroke or myocardial infarction), ordered by time to event, and (3) change from baseline in 6MW at 12 months. Additional prespecified secondary hierarchical and nonhierarchical endpoints are also being assessed. This trial is active at 20 clinical sites, including four sites in Canada and 120 patients have been enrolled to date.

 

Working with leading biostatistics and regulatory consultants, we submitted a supplement to the FDA in February 2023 with a proposed adaptive SAP for the CardiAMP Heart Failure trial. This was submitted as a Sprint Discussion under the Breakthrough designation guidance provided by the FDA. We met with the FDA CBER on March 29, 2023, documented the minutes of our discussion with the Agency and on April 26, 2023 submitted a detailed supplement for the implementation of an adaptive statistical analysis plan.

 

14

 

We anticipate that the next DSMB meeting will be scheduled in June 2023 and will utilize an adaptive design should the FDA approve the supplement as expected. In advance of the next DSMB review, we anticipate all data that contributes to the primary efficacy endpoint in the study submission will have been monitored by our clinical staff, verifying all clinical data required for interpretation in the DSMB review.

 

Should this next DSMB review or another future DSMB review include an adaptive statistical analysis plan, it could result in the DSMB being able to recommend the trial enrollment be stopped early for anticipated success with fewer patients or that confirmation of the study should continue as planned to the next DSMB review. Should we meet the primary endpoint with fewer patients than currently planned, the FDA Breakthrough designation granted to this program may reduce the need to have a significant additional number of patients to demonstrate safety prior to market approval and allow BioCardia to obtain additional safety data after market approval.

 

In July 2022, we had our second consultation with Japan’s Pharmaceutical and Medical Device Agency regarding potential approval of the CardiAMP Cell Therapy System for the treatment of ischemic heart failure based on existing data. After working with distinguished physician leaders, we are in the process of completing a formal submission towards approval in Japan. The submission has been submitted for translation into Japanese and is expected to be submitted to Pharmaceuticals and Medical Devices Agency (PMDA) by our regulatory consultants in the second quarter of 2023.  There is potential for subsequent submissions and consultations with PMDA based on the outcome from the current submission.

 

The CardiAMP Chronic Myocardial Ischemia Trial is a Phase III, multi-center, randomized, double-blinded, controlled study of up to 343 patients at up to 40 clinical sites. The Phase III pivotal trial is designed to provide the primary support for the safety and efficacy of the CardiAMP Cell Therapy System for the indication of chronic myocardial ischemia (BCDA-02). This therapeutic approach uses many of the same novel aspects as the CardiAMP Heart Failure Trial and is expected to leverage our experience and investment in the heart failure trial. The trial has been activated at two clinical sites and three patients have been treated. We are working to complete the roll-in cohort and work with the FDA to enhance the trial design before expanding this beyond four clinical centers.

 

The Department of Health and Human Services Centers for Medicare and Medicaid Services (CMS) has designated that both of our CardiAMP pivotal trials qualify for Medicare national coverage at up to $20,000 per patient. The covered costs under Medicare include patient screening, the CardiAMP Cell Therapy System and procedure, and clinical follow-up at one and two years after the procedure. Private insurance plans covering 50 million insured Americans follow the CMS reimbursement policy and are similarly anticipated to cover these costs. This coverage significantly reduces our cost of conducting these pivotal trials.

 

Allogeneic NK1R+ MSC Cell Therapy Platform

 

Our second therapeutic platform is our investigational culture expanded bone marrow derived allogeneic, Neurokinin-1 Receptor Positive Mesenchymal Stem Cells (NK1R+ MSC) for which the FDA approved two INDs in 2022. This “off the shelf” cell therapy is being advanced for ischemic heart failure of HFrEF (BCDA-03) and acute respiratory distress (BCDA-04). Variations of this allogeneic therapy may have the potential for numerous other therapeutic applications. These cells are compelling in part because they express the Neurkinin-1 receptor for the neuropeptide Substance P, an important neuropeptide associated with inflammation throughout the body and a primary mediator of inflammation in the airways. We manufacture these cells for clinical studies at its manufacturing facility in Sunnyvale which was certified for manufacturing in 2022. Clinical grade cells are available for both indications being pursued today.

 

Allogeneic NK1R+ MSC for Heart Failure and for Acute Respiratory Distress Syndrome

 

In December 2022, the FDA approved our Investigational New Drug (IND) application to initiate a first-in-human Phase I/II clinical trial to deliver these allogeneic cells for the treatment of HFrEF (BCDA-03). The trial is designed for patients with New York Heart Association Class II and III ischemic heart failure with ischemic HFrEF whose own cell composition makes them ineligible for the Company’s Phase III CardiAMP® Heart Failure Trial studying autologous cell therapy that has received FDA Breakthrough Device Designation. Efficiencies are expected in conducting this trial as patients who have been screened but are ineligible for enrollment in the CardiAMP Heart Failure trial would likely be eligible for this allogeneic trial. Clinical grade allogeneic cells have been manufactured and are ready for use and the cells will be delivered by our proprietary delivery system. We expect to begin enrolling patients in the second quarter of 2023.

 

In April 2022, the FDA approved the Company’s Investigational New Drug (IND) for a Phase I/II trial for the use of this allogeneic cell therapy for Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19 (BCDA-04). Fortunately, the number of patients with COVID-19 induced ARDS has decreased and the Company intends to work with the FDA to modify its inclusion criteria to include other patients with ARDS without requiring them to have previously had COVID-19.

 

15

 

The first part of the clinical trial will evaluate increasing dosages of the cells and the optimal dose will be taken to Phase II in a randomized study in adult patients recovering from ARDS. This therapy is intended to address the enormous unmet need of sustained local and systemic inflammation after a patient is taken off respirator support with goals of accelerating recovery, enhancing survival and reducing both relapse and rehospitalization. Clinical grade cells have been manufactured and are available for this study, but this trial initiation is expected to follow the initiation of the BCDA-03 trial of these allogeneic MSC for HFrEF.

 

Helix Biotherapeutic Delivery System

 

BioCardia’s Helix Biotherapeutic Delivery System (Helix) delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart. It enables local delivery of cell and gene-based therapies, including our own cell therapies to treat cardiac cardiovascular indications. The Helix catheter is CE marked in Europe and is under investigational use in the United States. The Helix design has served as a platform for our development of a number of transendocardial delivery system that are not clinically available yet. These are guided to the heart using a number of navigation platforms we have also developed.

 

BioCardia selectively partners its Helix Biotherapeutic Delivery Systems and broader biotherapeutic delivery capabilities with firms developing other cell, gene, and protein therapeutic programs. These partnered programs provide additional data, intellectual property rights, and opportunities to participate in the development of combination products for the treatment of cardiac diseases.

 

COVID-19 Considerations

 

As a result of the COVID-19 pandemic, we have experienced significant disruption to our business and delays in our development programs and regulatory and commercialization timelines, including adverse impact to our operations at certain clinical sites involved in our ongoing clinical studies. The COVID-19 pandemic could continue to adversely affect our business, results of operations, financial condition and/or liquidity in the future. These adverse impacts could include delayed or slowed enrollment of our, or our collaborators’, planned or ongoing clinical trials, delayed or cancelled clinical site initiations, delayed regulatory review for regulatory approvals, delayed commercialization of one or more of our product candidates, if approved, and workforce shortages. Our production capabilities, or those of our partners or suppliers, and our supply chains could also be adversely impacted.

 

Additionally, while the potential continuing economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of COVID-19 and related responses of governments, business and other institutions on the global financial markets may reduce the Company’s ability to access capital, which could negatively impact the Company’s liquidity and ability to raise the capital to complete its preclinical and clinical studies on a timely basis, or at all. In addition, a recession, market correction or depression resulting from the COVID-19 pandemic or the response to it could materially affect our business and the value of our common stock. 

 

Financial Overview

 

Revenue

 

We currently have a portfolio of enabling and delivery products, from which we have generated modest revenue. Net product revenues include commercial sales of our AVANCE steerable introducer and collaboration agreement revenues include revenue from partnering agreements with corporate and academic institutions. Under these partnering agreements, we provide our Helix biotherapeutic delivery system and customer training and support for use in preclinical and clinical studies.

 

Research and Development Expenses

 

Our research and development expenses consist primarily of:

 

 

salaries and related overhead expenses, which include share-based compensation and benefits for personnel in research and development functions;

 

 

fees paid to consultants and contract research organizations, or CROs, including in connection with our preclinical studies and clinical trials and other related clinical trial fees, such as for investigator grants, patient screening, laboratory work, clinical trial management and statistical compilation and analysis;

 

 

costs related to acquiring and manufacturing clinical trial materials;

 

 

costs related to compliance with regulatory requirements; and

 

 

payments related to licensed products and technologies.

 

16

 

We expense all research and development costs in the periods in which they are incurred. Costs for certain development activities are recognized based on an evaluation of the progress of completion of specific tasks using information and data provided to us by our vendors and clinical sites. Nonrefundable advance payments for goods or services to be received in future periods for use in research and development activities are deferred and capitalized. The capitalized amounts are then expensed as the related goods are delivered and the services are received. 

 

We plan to increase our research and development expenses for the foreseeable future as we continue the pivotal CardiAMP autologous cell therapy trials in heart failure and chronic myocardial ischemia, and begin our allogeneic cell therapy trials in heart failure and acute respiratory distress syndrome. We typically use our employee and infrastructure resources across multiple research and development programs, and accordingly, we have not historically allocated resources specifically to our individual programs. There are also significant synergies between these programs.

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses consist primarily of salaries and related costs for employees in executive, finance and administration, sales, corporate development and administrative support functions, including share-based compensation expenses and benefits. Other selling, general and administrative expenses include sales commissions, rent, accounting and legal services, obtaining and maintaining patents, the cost of consultants, occupancy costs, insurance premiums and information systems costs.

 

Other Income (Expense)

 

Other income and expense consist primarily of interest income we earn on our cash and cash equivalents. 

 

Critical Accounting Policies and Estimates

 

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with U.S. GAAP. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various judgements that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not clear from other sources. Actual results may differ from these estimates under different assumptions or conditions. 

 

We define our critical accounting policies as those that require us to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations as well as the specific manner in which we apply those principles. Our critical accounting policies are described in Item 7 in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 29, 2023, which is incorporated by reference herein. 

 

Results of Operations

 

Comparison of Three Months Ended March 31, 2023 and 2022

 

The following table summarizes our results of operations for the three months ended March 31, 2023 and 2022 (in thousands): 

 

   

Three months ended March 31,

 
   

2023

   

2022

 

Revenue:

               

Net product revenue

  $     $ 1  

Collaboration agreement revenue

    64       59  

Total revenue

    64       60  

Costs and expenses:

               

Research and development

    2,384       2,186  

Selling, general and administrative

    1,190       1,201  

Total costs and expenses

    3,574       3,387  

Operating loss

    (3,510 )     (3,327 )

Other income (expense):

               

Total other income, net

    9       2  

Net loss

  $ (3,501 )   $ (3,325 )

 

17

 

Revenue. Revenue increased to $64,000 in the three months ended March 31, 2023 as compared to $60,000 in the three months ended March 31, 2022, primarily due to the timing of revenue from new and existing collaborative partners coupled with the fulfilment of deliverables and completion of collaborative agreements. The amount and timing of collaboration revenues is largely dependent on our partners’ development activities and may be inconsistent and create significant quarter-to-quarter variation in our revenues.

 

Research and Development Expenses. Research and development expenses increased to $2,384,000 in the three months ended March 31, 2023 as compared to $2,186,000 in the three months ended March 31, 2022, primarily due to increasing expenses in support of the CardiAMP Heart Failure Trial.  

 

Selling, General and Administrative Expenses. Selling, general and administrative expenses decreased to $1,190,000 in the three months ended March 31, 2023 as compared to $1,201,000 in three months ended March 31, 2022.

 

Liquidity and Capital Resources

 

We have incurred net losses each year since our inception and as of March 31, 2023, we had an accumulated deficit of approximately $144.1 million. We anticipate that we will continue to incur net losses for the next several years.

 

We have funded our operations principally through the sales of equity and convertible debt securities. As of March 31, 2023, we had cash and cash equivalents of approximately $4.9 million. 

 

The following table shows a summary of our cash flows for the periods indicated (in thousands): 

 

   

Three months ended
March 31,

 
   

2023

   

2022

 

Net cash provided by (used in):

               

Operating activities

  $ (2,560 )   $ (2,913 )

Investing activities

    (10 )     (29 )

Financing activities

    64        

Net decrease in cash and cash equivalents

  $ (2,506 )   $ (2,942 )

 

Cash Flows from Operating Activities. The decrease in overall spending for operating activities of approximately $353,000 in the three months ended March 31, 2023 compared to the three months ended March 31, 2022 related primarily to improved working capital management. Cash flow from operating activities for any period is subject to many variables including the timing of cash receipts, payments to suppliers, and vendor payment terms.

 

18

 

Cash Flows from Investing Activities. Net cash used in investing activities of $10,000 and $29,000 during the three months ended March 31, 2023 and 2022 respectively, consisted of purchases of property and equipment, primarily lab and office equipment.

 

Cash Flows from Financing Activities. Net cash provided by financing activities of $64,000 during the three months ended March 31, 2023 related primarily to proceeds from the sale of common stock. 

 

Lincoln Park Capital Stock Purchase Agreement

 

On March 29, 2021, we entered into a purchase agreement with Lincoln Park Capital Fund, LLC (Lincoln Park) (Purchase Agreement) and a registration rights agreement (Registration Rights Agreement), pursuant to which we have the right to sell to Lincoln Park shares of our common stock having an aggregate value of up to $20 million, subject to certain limitations and conditions in the Purchase Agreement.

 

Pursuant to the Purchase Agreement in March, 2021, Lincoln Park purchased 373,832 shares of common stock, at a price of $5.35 per share, for a total gross purchase price of $2 million (Initial Purchase) and we issued 80,000 shares of common stock as commitment shares, which included 5,000 commitment shares issued on a pro rata basis for the initial $2 million purchase.

 

As of March 31, 2023, we had not sold any common stock to Lincoln Park under the Purchase Agreement other than the Initial Purchase.

 

Cantor Fitzgerald ATM Offering

 

On April 12, 2022, we entered into a sales agreement (Sales Agreement) with Cantor Fitzgerald & Co. (Cantor) as the sales agent, pursuant to which we may offer and sell, from time to time, through Cantor, shares of common stock having an aggregate offering price of up to $10.5 million (ATM Offering). We are not obligated to sell any common stock shares pursuant to the Sales Agreement. Under the terms of the Sales Agreement, we pay Cantor a commission of 3% of the aggregate proceeds from the sale of shares and reimburse certain legal fees. We filed a prospectus supplement under our existing registration statement covering the offer and sale of up to $10.5 million of common stock, of which approximately $8.5 million was still available for offer and sale as of March 31, 2023.

 

During the three months ended March 31, 2023, we sold 106,241 shares of common stock under the ATM Offering at then-market prices for total gross proceeds of $244,000, with net issuance costs of $13,000.

 

Future Funding Requirements

 

To date, we have generated modest revenues. We do not know when, or if, we will generate any revenue from our development stage biotherapeutic programs. We do not expect to generate any revenue from sales of our autologous and allogeneic cell therapy candidates unless and until we obtain regulatory approval. At the same time, we expect our expenses to increase in connection with our ongoing development activities, particularly as we continue the research, development and clinical trials of, and seek regulatory approval for, our therapeutic candidates. In addition, subject to obtaining regulatory approval for any of our therapeutic candidates and companion diagnostic, we expect to incur significant commercialization expenses for product sales, marketing, manufacturing and distribution. We anticipate that we will need additional funding in connection with our continuing operations.      

 

Based upon our current operating plan, we believe that the cash and cash equivalents of $4.9 million as of March 31, 2023 are not sufficient to fund our planned expenditures and meet our obligations beyond the third quarter of 2023. In order to continue development of our therapeutic candidates beyond the third quarter of 2023, we plan to raise additional capital, potentially including non-dilutive collaboration and licensing arrangements, debt or equity financing, or a combination from these sources. We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our therapeutic candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures necessary to complete the development of our therapeutic candidates.

 

Our future capital requirements will depend on many factors, including:

 

 

the progress, costs, results and timing of our autologous CardiAMP Cell Therapy System and allogeneic Neurokinin-1 Receptor Positive clinical trials and related development programs;

 

 

FDA acceptance of our autologous CardiAMP Cell Therapy System and allogeneic Neurokinin-1 Receptor Positive therapies for heart failure and for other potential indications;

 

19

 

 

the outcome, costs and timing of seeking and obtaining FDA and any other regulatory approvals;

 

 

the costs associated with securing, establishing and maintaining commercialization and manufacturing capabilities;

 

 

the number and characteristics of product candidates that we pursue, including our product candidates in preclinical development;

 

 

the ability of our product candidates to progress through clinical development successfully;

 

 

our need to expand our research and development activities;

 

 

the costs of acquiring, licensing, or investing in businesses, products, product candidates and technologies;

 

 

our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;

 

 

the general and administrative expenses related to being a public company;

 

 

our need and ability to hire additional management and scientific, medical and sales personnel;

 

 

the effect of competing technological and market developments;

   

 

 

our need to implement additional internal systems and infrastructure, including financial and reporting systems; and

 

 

the cost of the impact from the COVID-19 pandemic.

 

Until such time that we can generate meaningful revenue from the sales of approved therapies and products, if ever, we expect to finance our operating activities through public or private equity or debt financings, government or other third-party funding, marketing and distribution arrangements, and other collaborations, strategic alliances and licensing arrangements or a combination of these approaches. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include conversion discounts or covenants limiting or restricting our ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through government or other third-party funding, marketing and distribution arrangements or other collaborations, or strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, products, or therapeutic candidates or to grant licenses on terms that may not be favorable to us.

 

Our condensed consolidated financial statements as of March 31, 2023 have been prepared on the basis that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. Due to the factors described above, there is substantial doubt about our ability to continue as a going concern within one year after the date these financial statements are issued. Our ability to continue as a going concern will depend in a large part, on our ability to raise additional capital. If adequate funds are not available, we may be required to reduce operating expenses, delay or reduce the scope of our product development programs, obtain funds through arrangements with others that may require us to relinquish rights to certain of our technologies or products that we would otherwise seek to develop or commercialize ourselves, or cease operations. While we believe in the viability of our strategy to raise additional funds, there can be no assurances that we will be able to obtain additional capital on acceptable terms and in the amounts necessary to fully fund our operating needs.

 

The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. If we are unable to continue as a going concern, we may be forced to liquidate assets. In such a scenario, the values received for assets in liquidation or dissolution could be significantly lower than the values reflected in our condensed consolidated financial statements. 

 

Off-Balance Sheet Arrangements

 

During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under the rules of the Securities and Exchange Commission.

 

Recent Accounting Pronouncements

 

See Note 2 of our notes to condensed consolidated financial statements for information regarding recent accounting pronouncements that are of significance or potential significance to us.

 

20

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

There have been no material changes in our market risks during the three months ended March 31, 2023.

 

Our exposure to market risk is currently limited to our cash and cash equivalents, all of which have maturities of less than three months. The goals of our investment policy are preservation of capital, maintenance of liquidity needs, and fiduciary control of cash and investments. We also seek to maximize income from our investments without assuming significant risk or departing from our investment policy. We currently do not hedge interest rate exposure. Because of the short-term nature of our cash equivalents, we do not believe that an increase in market rates would have a material negative impact on the value of our portfolio.

 

Interest Rate Risk

 

As of March 31, 2023, based on current interest rates and total borrowings outstanding, a hypothetical 100 basis point increase or decrease in interest rates would have an immaterial pre-tax impact on our results of operations.

 

Foreign Currency Exchange Risks

 

We are a U.S. entity and our functional currency is the U.S. dollar. The vast majority of our revenues were derived from sales in the United States. We have business transactions in foreign currencies; however, we believe we do not have significant exposure to risk from changes in foreign currency exchange rates at this time. We do not currently engage in hedging or similar transactions to reduce our foreign currency risks. We will continue to monitor and evaluate our internal processes relating to foreign currency exchange, including the potential use of hedging strategies.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

In connection with the preparation of this Quarterly Report on Form 10-Q, as of March 31, 2023, an evaluation was performed under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of March 31, 2023, our disclosure controls and procedures were, in design and operation, effective at a reasonable assurance level.

 

Changes in Internal Control over Financial Reporting

 

There were no changes to our internal control over financial reporting identified in connection with the evaluation required by rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the three months ended March 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

21

 

 

PART II. OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

The Company may be subject to various claims, complaints, and legal actions that arise from time to time in the normal course of business. Management does not believe that the Company is party to any current pending legal proceedings. There can be no assurance that existing or future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on the Company’s business, financial position, results of operations, or cash flows.  

 

ITEM 1A. RISK FACTORS

 

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2022, which could materially affect our business, financial condition, or future results, are incorporated by reference herein. The risks described in this report, our Annual Report on Form 10-K for the year ended December 31, 2022, and our Quarterly Reports on Form 10-Q filed periodically with the SEC are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.  

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

None.

 

ITEM 6. EXHIBIT INDEX

 

Exhibit

Number 

Exhibit Description

   

3.1(1)

Amended and Restated Certificate of Incorporation, as amended May 6, 2019

3.2(2)

Amended and Restated Bylaws

31.1*

Certification of Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*

Certification of Principal Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.

32.1**

Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2**

Certification of Principal Financial Officer Pursuant to Rule 13a-14(b) and Section 906 of the Sarbanes-Oxley Act of 2002.

   

101.INS+

Inline XBRL Instance Document

101.SCH+

Inline XBRL Taxonomy Extension Schema Document

101.CAL+

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF+

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB+

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE+

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

*

Filed herewith.

**

Furnished herewith.

+

The financial information contained in these XBRL documents is unaudited and is furnished, not filed with the Securities and Exchange Commission.

(1)

Previously filed as Exhibit 3.1 to the Form 10-Q for the quarterly period ended June 30, 2019 filed by us on August 14, 2019.

(2)

Previously filed as Exhibit 3.2 to the Current Report on Form 8-K filed by us on April 11, 2017.

 

22

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

BIOCARDIA, INC.

(Registrant)

     
     

Date:                        May 10, 2023

By:

/s/ Peter Altman

   

Peter Altman

   

President and Chief Executive Officer

   

(Principal Executive Officer)

     
     

Date:                        May 10, 2023

By:

/s/ David McClung

   

David McClung

   

Chief Financial Officer

   

(Principal Financial and Accounting Officer)

 

23
EX-31.1 2 ex_511786.htm EXHIBIT 31.1 ex_511786.htm

Exhibit 31.1

 

Certification of Principal Executive Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Peter Altman, certify that:

 

1.        I have reviewed this Quarterly Report on Form 10-Q of BioCardia, Inc.;

 

2.       Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.       Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.        The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

(c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

(d)

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.       The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date:                           May 10, 2023

 

/s/ Peter Altman

 
 

Name: Peter Altman

 
 

Title: President and Chief Executive Officer

(Principal Executive Officer)

 

 

 

 
EX-31.2 3 ex_511787.htm EXHIBIT 31.2 ex_511787.htm

Exhibit 31.2

 

Certification of Principal Financial Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, David McClung, certify that:

 

1.        I have reviewed this Quarterly Report on Form 10-Q of BioCardia, Inc.;

 

2.       Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.       Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.       The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

   

 

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

   

 

 

(c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

   

 

 

(d)

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.       The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date:                         May 10, 2023

 

/s/ David McClung

 
 

Name: David McClung

 
 

Title: Chief Financial Officer

(Principal Financial Officer)

 

 

 

 
EX-32.1 4 ex_511788.htm EXHIBIT 32.1 ex_511788.htm

Exhibit 32.1

 

Certification of Principal Executive Officer

 

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Peter Altman, the President and Chief Executive Officer of BioCardia, Inc. (the "Company"), hereby certify, that, to my knowledge:

 

1.      The Quarterly Report on Form 10-Q for the period ended March 31, 2023 (the "Report") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.      The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date:                       May 10, 2023

 

/s/ Peter Altman

 
 

Name: Peter Altman

 
 

Title: President and Chief Executive Officer

(Principal Executive Officer)

 

 

 

 
EX-32.2 5 ex_511789.htm EXHIBIT 32.2 ex_511789.htm

Exhibit 32.2

 

Certification of Principal Financial Officer

 

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, David McClung, the Chief Financial Officer of BioCardia, Inc. (the “Company”), hereby certify, that, to my knowledge:

 

1.       The Quarterly Report on Form 10-Q for the period ended March 31, 2023 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.       The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date:                         May 10, 2023

 

/s/ David McClung

 
 

Name: David McClung

 
 

Title: Chief Financial Officer

(Principal Financial Officer)

 

 

 

 

 

 
EX-101.SCH 6 bcda-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 1 - Summary of Business and Basis of Presentation link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 2 - Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 3 - Fair Value Measurement link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 4 - Property and Equipment, Net link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 5 - Operating Lease Right-of-use Asset, Net link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 7 - Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 8 - Share-based Compensation link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 9 - Net Loss Per Share link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 10 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 11 - Related Party Transactions link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 12 - Contingencies and Contingencies link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 3 - Fair Value Measurement (Tables) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 4 - Property and Equipment, Net (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 5 - Operating Lease Right-of-use Asset, Net (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 7 - Stockholders' Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 8 - Share-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 9 - Net Loss Per Share (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 2 - Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 3 - Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 4 - Property and Equipment, Net (Details Textual) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 4 - Property and Equipment, Net - Summary of Property and Equipment, Net (Details) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 5 - Operating Lease Right-of-use Asset, Net (Details Textual) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 5 - Operating Lease Right-of-use Asset, Net - Future Minimum Lease Payments Under Operating Lease (Details) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 7 - Stockholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 7 - Stockholders' Equity - Warrants (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 8 - Share-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 8 - Share-based Compensation - Share-based Compensation Expense (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 8 - Share-based Compensation - Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 9 - Share-based Compensation - Summary of Non-vested RSUs (Details) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 9 - Net Loss Per Share - Anti-dilutive Securities (Details) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 10 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 11 - Related Party Transactions (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 7 bcda-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 bcda-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Note To Financial Statement Details Textual us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths 2024 Significant Accounting Policies us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo 2025 Note 3 - Fair Value Measurement Note 4 - Property and Equipment, Net Note 5 - Operating Lease Right-of-use Asset, Net Note 6 - Accrued Expenses and Other Current Liabilities Note 7 - Stockholders' Equity Note 8 - Share-based Compensation Note 9 - Net Loss Per Share Note 3 - Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details) Income Tax Disclosure [Text Block] Note 4 - Property and Equipment, Net - Summary of Property and Equipment, Net (Details) Note 5 - Operating Lease Right-of-use Asset, Net - Future Minimum Lease Payments Under Operating Lease (Details) Other assets us-gaap_ShareBasedCompensation Share-based compensation Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) us-gaap_LiabilitiesCurrent Total current liabilities us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Remainder of 2023 Note 7 - Stockholders' Equity - Warrants (Details) Note 8 - Share-based Compensation - Share-based Compensation Expense (Details) Note 8 - Share-based Compensation - Stock Option Activity (Details) Note 9 - Share-based Compensation - Summary of Non-vested RSUs (Details) Payable to related party Other Liabilities, Current Note 9 - Net Loss Per Share - Anti-dilutive Securities (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] Share-Based Payment Arrangement, Option, Activity [Table Text Block] RSUs released (in dollars per share) Balance, March 31, 2023 (in dollars per share) Balance, December 31, 2022 (in dollars per share) Balance, March 31, 2023 (in shares) Balance, December 31, 2022 (in shares) us-gaap_Depreciation Depreciation us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod RSUs released (in shares) Depreciation Collaboration Agreement [Member] Represents the information pertaining to the collaboration agreement. Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] us-gaap_SharesIssuedPricePerShare Shares Issued, Price Per Share us-gaap_AssetsCurrent Total current assets Exercisable, March 31, 2023 (in dollars per share) us-gaap_CashAndCashEquivalentsFairValueDisclosure Money market funds Exercisable, March 31, 2023 (Year) Exercisable, March 31, 2023 Equity [Text Block] Exercisable, March 31, 2023 (in shares) bcda_MaximumDiscountOnLegalService Maximum Discount on Legal Service Maximum discount on legal service. Balance, December 31, 2022 (Year) Balance, December 31, 2022 Common stock, $0.001 par value, 100,000,000 shares authorized, 20,202,005 and 20,076,773 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively Adjustments to reconcile net loss to net cash used in operating activities: Measurement Frequency [Axis] Measurement Frequency [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Balance, December 31, 2022 (in dollars per share) Balance, March 31, 2023 (in dollars per share) Fair Value, Recurring [Member] us-gaap_CommonStockSharesAuthorized Common Stock, Shares Authorized (in shares) Stock options forfeited (in dollars per share) Deferred revenue Common Stock, Shares, Issued (in shares) us-gaap_CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share (in dollars per share) Stock options exercised (in dollars per share) Accrued expenses us-gaap_OperatingLeasePayments Operating Lease, Payments Lessee, Operating Leases [Text Block] Accounts payable Product and Service [Axis] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Balance, December 31, 2022 (in shares) Balance, March 31, 2023 (in shares) Product and Service [Domain] Preferred stock, $0.001 par value, 25,000,000 shares authorized and no shares issued and outstanding as of March 31, 2023 and December 31, 2022 us-gaap_PolicyTextBlockAbstract Accounting Policies Accrued salaries and employee benefits Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided and employee benefits (due within one year or within the normal operating cycle if longer). Property, Plant and Equipment Disclosure [Text Block] Property, Plant and Equipment [Table Text Block] us-gaap_PreferredStockSharesAuthorized Preferred Stock, Shares Authorized (in shares) Unpaid issuance costs of common stock us-gaap_PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share (in dollars per share) Net product revenue ATM [Member] Represents ATM agreement. Fair Value, Inputs, Level 3 [Member] us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchase of property and equipment Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Axis] Employees, Non-employees and Non-employee Directors [Member] Represents Employees, Non-employees and Non-employee Directors Current liabilities: Product [Member] us-gaap_Assets Total assets Deferred revenue us-gaap_IncreaseDecreaseInDeferredRevenue Warrants for common stock exercised (in dollars per share) The weighted average exercise price of warrants exercised during the period. us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Operating activities: us-gaap_OperatingLeaseExpense Operating Lease, Expense us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Statement [Line Items] Accounts Receivable, Allowance for Credit Loss, Current Accounts receivable, net of allowance for doubtful accounts of $11 as of both March 31, 2023 and December 31, 2022 Furniture and Fixtures [Member] Additional paid-in capital Share-Based Payment Arrangement [Text Block] Stockholders’ equity: Leasehold Improvements [Member] Total other income, net Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Business Description and Basis of Presentation [Text Block] Award Type [Domain] Warrants for common stock sold (in dollars per share) Weighted average exercise price per share or per unit of warrants or rights issued during the period. Underwriters [Member] Represents the information pertaining to the underwriters. Current assets: Fair Value Disclosures [Text Block] Net loss Net loss Award Type [Axis] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Restricted Stock Units (RSUs) [Member] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net change in cash and cash equivalents us-gaap_Liabilities Total liabilities us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by financing activities Commitments and Contingencies Sale of Stock [Axis] Sale of Stock [Domain] us-gaap_OperatingIncomeLoss Operating loss Other income (expense): us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities Share-Based Payment Arrangement, Option [Member] Warrant [Member] Prepaid expenses and other current assets us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Accrued expenses and other current liabilities Total Amount of accrued liabilities and liabilities classified as other, due within one year or the normal operating cycle, if longer. Counterparty Name [Axis] Counterparty Name [Domain] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Less accumulated depreciation Property and equipment, net Property and equipment, net Contingencies Disclosure [Text Block] Schedule of Accrued Liabilities and Other Current Liabilities [Table Text Block] Tabular disclosure of the components of accrued liabilities and other current liabilities. Accrued Liabilities and Other Current Liabilities Disclosure [Text Block] The entire disclosure for accrued liabilities and other current liabilities at the end of the reporting period. Grant liability Amount of obligations incurred for grants, payable within one year or the normal operating cycle, if longer. Computer equipment and software us-gaap_PaymentsOfStockIssuanceCosts Issuance costs of sale of common stock Payments of Stock Issuance Costs Concentration Risk, Credit Risk, Policy [Policy Text Block] Customer deposits The amount of customer deposit liabilities classified as current. us-gaap_CostsAndExpenses Total costs and expenses Costs and expenses: Investing activities: Retained Earnings [Member] Earnings Per Share [Text Block] Proceeds from sales of common stock Proceeds from Issuance of Common Stock